Science & Enterprise subscription

Follow us on Twitter

  • A company using image analysis and deep learning to discover therapies for diseases often considered difficult to t… https://t.co/rnoQVhLISa
    about 46 mins ago
  • New post on Science and Enterprise: A.I. Discovery Company Raises $123M in Venture Funds https://t.co/2gXLZgLu0f #Science #Business
    about 49 mins ago
  • A clinical trial is underway assessing a drug approved for a rare inherited disease as a treatment for people hospi… https://t.co/Jyaa0PlA4A
    about 7 hours ago
  • New post on Science and Enterprise: Trial Testing Rare Disease Drug for Covid-19 Pneumonia https://t.co/2hAsoiN16x #Science #Business
    about 7 hours ago
  • Discoveries in a university lab that enable detection of Covid-19 infections from a person's breath are being licen… https://t.co/DgmvR2EcTr
    about 23 hours ago

Please share Science & Enterprise

Patent Granted for Lung Disorder Treatment

Illustration of lungs (Mikael Häggström/Wikimedia Commons)

(Mikael Häggström/Wikimedia Commons)

Discovery Laboratories Inc., a biotechnology company in Warrington, Pennsylvania, said today the company received a U.S. patent for its treatment of pulmonary inflammation. The patent — number 7,863,241 — expires in 2023.

Discovery Labs says the patent covers its KL4 peptide (also known as sinapultide), an engineered pulmonary surfactant that lowers surface tension and promote oxygen exchange. The patented treatment delivers an array of protease inhibitors, administered as either a liquid or aerosol, for treating pulmonary inflammation.

The company credits Charles Cochrane, co-founder of The Scripps Research Institute, as the original inventor of Discovery Labs’ surfactant technology. The Scripps Research Institute has granted Discovery Labs exclusive licensing rights for this patent.

*     *     *

Comments are closed.